Immuno-Oncology Products and Services
Accelerate Cancer Immunotherapy Drugs with Fast and Clinically Relevant Assays
DiscoverX offers a comprehensive portfolio of products and services that enable fast, effective, and clinically relevant understanding of immuno-oncology targets, pathways and mechanisms, enabling quicker development of immuno-oncology drugs. Learn how you can rapidly screen and develop antibodies targeting checkpoint receptors, bi-specific antibodies, small molecules, or cellular therapies such as chimeric antigen receptor T-cells (CAR-T).
|
Enabling Development of Cancer Immunotherapy Drugs
From Discovery to Combination Therapies
Developing drugs that target immune checkpoint receptors presents us with challenges starting from the identification of the best lead molecule to the in vitro testing of appropriate drug combinations before putting them into patients. DiscoverX uses a variety of target-, phenotypic- and pathway-based approaches to enable you to make better cancer immunotherapies, faster.
Watch Webinar |
Model Complexity of Tumor Microenvironments
BioMAP Oncology Systems
The BioMAP Oncology Systems model the complexity of different tumor microenvironments (TME) by combining primary human stromal or vascular cells with immune cells and human tumor cell lines to mimic interactions and signaling pathways that occur during tumorigenesis. Use Oncology Panels to gain insight into TME specific mechanism of action, efficacy and safety-related effects of test agents.
Learn More Request Quote |
|
Maximize Immunotherapies by Identifying Synergistic Combinations
Evaluate the Effect of Drug Combinations with BioMAP
Combo ELECT
The BioMAP Combo ELECT service allows statistical evaluation of drug combinations to determine additive or antagonistic differences between drug agents in a nominated disease model of interest. Each agent is analyzed individually, and then statistically compared against a combination array of the two serially diluted agents. Use Combo ELECT to inform on the optimal dosing, potential synergy, or adverse effects of different drug pairings.
Learn More Request Quote
|
Specifically Measure Target Cell Death in Co-Cultures with No Donor Variability
KILR® Cytotoxicity Assays
The KILR Cytotoxicity assay is an easy-to-use, non-radioactive and dye-free method to specifically and sensitively measure target cell death in a co-culture with immune effector cells. Use this assay to detect cancer cell death for applications like ADCC, CDC, ADCP, T-cell redirection and CAR-T. Single donor-derived KILR CD16 Effector Cells deliver large assay windows and are compatible with any ADCC assay to measure target cell death.
Learn More
|
|
Easily Screen & Optimize Drugs Targeting Checkpoint Receptors
Assays for Co-Stimulatory and Co-Inhibitory Receptors
The PathHunter® Checkpoint assays enable screening, lead optimization, and potency assay development of small molecule and biologic drugs. These biologically relevant cell-based assays do not require any primary tissues, have an easy-to-use protocol, and provide a highly sensitive response in less than 5 hours. Save months of assay development time with the industry’s largest menu of checkpoint receptor cell-based assays.
Products Services
|
Define Off-Target Biology Effects, Outside the Tumor Microenvironment
BioMAP Diversity PLUS™
Test agents across a broad range of human tissue biology with Diversity PLUS, which is used to inform on the potency, selectivity, safety, mechanism of action, and disease indication of a test agent.
Learn More Request Quote |
|
Accelerate Drugs Targeting Interleukin Receptors
Functional Assays for over 85% of Human Interleukins
The PathHunter Interleukin Assays offer a comprehensive portfolio of cell-based assays to enable the study and targeting of human interleukin proteins and their receptors. The assays are highly specific, with an easy-to-use protocol, rapid results, high matrix tolerance, and high reproducibility. They have broad usage in functional screening, characterization, QC lot release assays, and neutralizing antibody studies.
Products Services
|
Webinars
Enabling Development of Cancer Immunotherapy Drugs – From Discovery to Combination Strategies
Watch Webinar
Leveraging Predictive Human Adaptive Immune Cell Models for Drug Discovery
Watch Webinar
Simple, Functional Cell-based Assays for Human Interleukins
Watch Webinar
Specifically Measure Target Cell Death for ADCC, ADCP, BiTe-like Bispecifics, & CAR-T
Watch Webinar
Building Relevant Cell-Based Assays for Co-Stimulatory & Co-Inhibitory Checkpoint Receptors
Watch Webinar